Drug intelligence / Profile preview

Hongjin Xiaojie tablets

Development stage: Unknown
Lead developer: Tibet Aim Pharm
Administration: Oral

Overview

Hongjin Xiaojie tablets (also marketed under the brand name Meixiaodan) are an approved traditional Chinese medicine (TCM) tablet developed by Tibet Aim Pharm and manufactured by its subsidiary Sichuan Weiao Pharmaceutical. Formulated from a blend of traditional herbs including Notoginseng, Rhizoma Cyperi, Bupleurum, and Golden Buckwheat, the tablets are designed to soothe the liver, regulate Qi, soften hard masses, disperse nodules, and promote blood circulation to resolve blood stasis. Hongjin Xiaojie tablets are primarily indicated for the treatment of gynecological and obstetric conditions associated with Qi stagnation and blood stasis, such as lobular hyperplasia of the mammary gland (breast hyperplasia), uterine fibroids (hysteromyoma), and ovarian cysts.

Brand names: Meixiaodan美消丹
Other names: Hongjin Xiaojie Pian红金消结片

Beyond the preview

Go deeper on Hongjin Xiaojie tablets.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hongjin Xiaojie tablets.